<p>/PRNewswire/ -- Premier Research，一家全球領先的臨牀研究和諮詢服務公司，今天宣佈任命 Siân Ratcliffe Smethurst 博士為首席運營官。</p>
<p>擁有超過 25 年生物製藥行業的科學和運營領導經驗，Ratcliffe Smethurst 博士將負責組織的臨牀研究和開發。在這個角色中，她將推動所有臨牀開發職能的運營和質量表現，包括研究設計和交付、數據管理和監管支持。</p>
<p>&#34;我很高興歡迎 Siân 加入我們的執行團隊，擔任首席運營官，&#34; Premier 首席執行官 John Ratliff 説。&#34;這一戰略任命支持 Premier 對高質量臨牀交付和運營可擴展性的承諾。我們相信 Siân 將推動我們的臨牀能力，改善現場和患者體驗，併為我們的客户提升價值。&#34;</p>
<p>在加入 Premier 之前，Ratcliffe Smethurst 博士曾在 Biogen 和 Pfizer 擔任多個高級領導職務，涵蓋研究、開發和醫學的所有階段，以及多個治療領域，包括腫瘤學、神經學、精神病學、疼痛、罕見疾病、免疫學、內科、女性健康和疫苗。最近，Ratcliffe Smethurst 博士在 Biogen 擔任 SVP、定量科學與開發運營（QSDO）負責人，領導一個大型全球團隊，負責 Biogen 臨牀試驗組合的設計、戰略規劃、執行和分析。</p>
<p>&#34;我對能夠為 Premier 的長期願景做出貢獻感到振奮，並期待與一支敬業且經驗豐富的團隊合作，&#34; Ratcliffe Smethurst 博士説。&#34;我們共同的承諾是將突破性的科學轉化為改變生活的療法，為患者帶來真正的改變，同時為我們的利益相關者提供持久的價值。&#34;</p>
<p><strong>關於 Premier Research</strong> Premier Research International LLC（Premier）是一家全球領先的臨牀研究和諮詢服務公司，專注於為生命科學行業提供高效有效的市場路徑。Premier 以生物技術的需求為基礎，通過解決試驗複雜性、克服開發障礙和展示產品價值，將突破性的科學轉化為改變生活的藥物、設備和診斷。憑藉深厚的治療專業知識、創新技術和產品開發運營能力——從臨牀前規劃到臨牀試驗執行和商業化——我們的綜合方法提供個性化的端到端解決方案，以識別做出明智決策所需的相關數據和洞察，並加快開發時間表，為更智能、更快速的批准路徑提供支持。欲瞭解更多信息，請訪問 premier-research.com。</p>
<p><strong>媒體聯繫人：</strong> Amber Frasketi</p>
<p>市場副總裁</p>
<p>[email protected]</p>
<p>+1 (919) 616-2431</p>
<p>來源 Premier Research International LLC</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA2Jk5ld3NJdGVtSWQ9Q0w1NjUwOCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDYwNzU1UFJfTkVXU19VU1BSX19fX19DTDU2NTA4?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA2Jk5ld3NJdGVtSWQ9Q0w1NjUwOCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDYwNzU1UFJfTkVXU19VU1BSX19fX19DTDU2NTA4"/></p>

PINC

<p>Premier Research 任命 Siân Ratcliffe Smethurst 博士為首席運營官。她在生物製藥行業擁有超過 25 年的經驗，將負責臨牀研究和開發，提升運營績效和質量。首席執行官 John Ratliff 對她改善臨牀能力和客户價值的能力表示信心。Ratcliffe Smethurst 博士曾在 Biogen 和 Pfizer 擔任高級職務，專注於多個治療領域。她旨在為 Premier 的願景貢獻力量，將科學轉化為有影響力的療法</p>

<p>, /PRNewswire/ -- Premier Research, a global leader in clinical research and consulting services, announced today the appointment of Siân Ratcliffe Smethurst, Ph.D., to the position of Chief Operating Officer.</p>
<div class="lb-trans"><p>/PRNewswire/ -- Premier Research，一家全球領先的臨牀研究和諮詢服務公司，今天宣佈任命 Siân Ratcliffe Smethurst 博士為首席運營官。</p>
</div><p>With more than 25 years of scientific and operational leadership in the biopharmaceutical industry, Dr. Ratcliffe Smethurst will oversee the organization's Clinical Research and Development. In this role, she will drive operational and quality performance across all clinical development functions, including study design and delivery, data management, and regulatory support.</p>
<div class="lb-trans"><p>擁有超過 25 年生物製藥行業的科學和運營領導經驗，Ratcliffe Smethurst 博士將負責組織的臨牀研究和開發。在這個角色中，她將推動所有臨牀開發職能的運營和質量表現，包括研究設計和交付、數據管理和監管支持。</p>
</div><p>&#34;I am pleased to welcome Siân to our executive team as Chief Operating Officer,&#34; said Premier Chief Executive Officer, John Ratliff. &#34;This strategic appointment supports Premier's commitment to high-quality clinical delivery and operational scalability. We are confident Siân will propel our clinical capabilities, improve the site and patient experience, and enhance value for our customers.&#34;</p>
<div class="lb-trans"><p>&#34;我很高興歡迎 Siân 加入我們的執行團隊，擔任首席運營官，&#34; Premier 首席執行官 John Ratliff 説。&#34;這一戰略任命支持 Premier 對高質量臨牀交付和運營可擴展性的承諾。我們相信 Siân 將推動我們的臨牀能力，改善現場和患者體驗，併為我們的客户提升價值。&#34;</p>
</div><p>Prior to joining Premier, Dr. Ratcliffe Smethurst served in multiple senior leadership roles at Biogen and Pfizer spanning all phases of Research, Development, and Medical as well as multiple therapeutic areas, including Oncology, Neurology, Psychiatry, Pain, Rare Disease, Immunology, Internal Medicine, Women's Health, and Vaccines. Most recently, Dr. Ratcliffe Smethurst held the role of SVP, Head of Quantitative Sciences &amp; Development Operations (QSDO) at Biogen, where she led a large global team accountable for the design, strategic planning, execution, and analysis of Biogen's clinical trial portfolio.</p>
<div class="lb-trans"><p>在加入 Premier 之前，Ratcliffe Smethurst 博士曾在 Biogen 和 Pfizer 擔任多個高級領導職務，涵蓋研究、開發和醫學的所有階段，以及多個治療領域，包括腫瘤學、神經學、精神病學、疼痛、罕見疾病、免疫學、內科、女性健康和疫苗。最近，Ratcliffe Smethurst 博士在 Biogen 擔任 SVP、定量科學與開發運營（QSDO）負責人，領導一個大型全球團隊，負責 Biogen 臨牀試驗組合的設計、戰略規劃、執行和分析。</p>
</div><p>&#34;I am energized by the opportunity to contribute to Premier's long-term vision and look forward to collaborating with a committed and experienced team,&#34; said Dr. Ratcliffe Smethurst. &#34;Our shared commitment is to turn breakthrough science into life-changing therapies that make a real difference for patients, while delivering enduring value for our stakeholders.&#34;</p>
<div class="lb-trans"><p>&#34;我對能夠為 Premier 的長期願景做出貢獻感到振奮，並期待與一支敬業且經驗豐富的團隊合作，&#34; Ratcliffe Smethurst 博士説。&#34;我們共同的承諾是將突破性的科學轉化為改變生活的療法，為患者帶來真正的改變，同時為我們的利益相關者提供持久的價值。&#34;</p>
</div><p><strong>About Premier Research</strong> Premier Research International LLC (Premier) is a global leader in clinical research and consulting services with expertise in driving an efficient and effective path to market for the life sciences industry. Premier is built with the needs of biotech in mind, turning breakthrough science into life-changing drugs, devices, and diagnostics by addressing trial complexity, overcoming development hurdles, and demonstrating product value. Leveraging deep therapeutic expertise, innovative technology, and product development operational proficiency—from preclinical planning to clinical trial execution and commercialization—our integrated approach offers personalized, end-to-end solutions to identify the pertinent data and insight necessary to make informed decisions earlier and deliver accelerated development timelines for a smarter, faster path to approval. To learn more visit premier-research.com.</p>
<div class="lb-trans"><p><strong>關於 Premier Research</strong> Premier Research International LLC（Premier）是一家全球領先的臨牀研究和諮詢服務公司，專注於為生命科學行業提供高效有效的市場路徑。Premier 以生物技術的需求為基礎，通過解決試驗複雜性、克服開發障礙和展示產品價值，將突破性的科學轉化為改變生活的藥物、設備和診斷。憑藉深厚的治療專業知識、創新技術和產品開發運營能力——從臨牀前規劃到臨牀試驗執行和商業化——我們的綜合方法提供個性化的端到端解決方案，以識別做出明智決策所需的相關數據和洞察，並加快開發時間表，為更智能、更快速的批准路徑提供支持。欲瞭解更多信息，請訪問 premier-research.com。</p>
</div><p><strong>Media Contact:</strong> Amber Frasketi</p>
<div class="lb-trans"><p><strong>媒體聯繫人：</strong> Amber Frasketi</p>
</div><p>Vice President, Marketing</p>
<div class="lb-trans"><p>市場副總裁</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>+1 (919) 616-2431</p>
<div class="lb-trans"><p>+1 (919) 616-2431</p>
</div><p>SOURCE Premier Research International LLC</p>
<div class="lb-trans"><p>來源 Premier Research International LLC</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwMTA2Jk5ld3NJdGVtSWQ9Q0w1NjUwOCZUcmFuc21pc3Npb25fSWQ9MjAyNjAxMDYwNzU1UFJfTkVXU19VU1BSX19fX19DTDU2NTA4" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=CL56508&amp;Transmission_Id=202601060755PR_NEWS_USPR_____CL56508&amp;DateId=20260106"/></p>

Siân Ratcliffe Smethurst 被任命為 Premier Research 的首席運營官